<html>
<head><title>
Prepared and filed by St Ives Financial
</title>
</head>
<body bgcolor="#FFFFFF">
<page>
 <p align="center"><font size="2" face="serif"><b>UNITED STATES<br>
</b></font><font size="2" face="serif"><b>SECURITIES AND EXCHANGE COMMISSION<br>
</b></font><font size="2" face="serif"><b>Washington, D. C.  20549</b></font></p>
<p align="center"><font size="2" face="serif"><b>___________</b></font></p>
<p align="center"><font size="2" face="serif"><b>FORM 8-K</b></font></p>
<p align="center"><font size="2" face="serif"><b>CURRENT REPORT</b></font></p>
<p align="center"><font size="2" face="serif"><b>Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</b></font></p>
<p align="center"><font size="2" face="serif"><b>October 19, 2006<br>
</b></font><font size="2" face="serif">Date of report (Date of earliest event reported)</font></p>
<p align="center"><b><font face="serif" size="3">APPLERA CORPORATION<br>
</font></b><font size="2" face="serif">(Exact name of registrant as specified in its charter)</font></p>
<table width="100%" cellspacing="0" cellpadding="0" border="0">
<tr valign="top">
  <td width="33%" align="center"><font size="2" face="serif">&nbsp;<b>Delaware</b></font></td>
<td width="33%" align="center"><font size="2" face="serif">&nbsp;<b>001-04389</b></font></td>
<td align="center"><font size="2" face="serif"><b>06-1534213</b></font></td>
</tr>
<tr valign="top">
  <td align="center"><font size="2" face="serif">(State or other jurisdiction<br>
    of incorporation)  </font></td>
  <td align="center"><font size="2" face="serif">(Commission<br>
    file
number)  </font></td>
  <td align="center"><font size="2" face="serif">(IRS Employer<br>
  </font><font size="2" face="serif">Identification No.)</font></td>
</tr>
</table>
<p align="center"><font size="2" face="serif"><b>301 Merritt 7<br>
</b></font><font size="2" face="serif"><b>Norwalk, Connecticut  06851<br>
</b></font><font size="2" face="serif">(Address of principal executive offices, including zip code)</font></p>
<p align="center"><font size="2" face="serif"><b>(203) 840-2000<br>
</b></font><font size="2" face="serif">(Registrant&#146;s
telephone number, including area code)</font></p>
<p align="center"><font size="2" face="serif"><b>N/A<br></b>(Former name or former address, if changed since last report)<br></font></p>
<p align="left"><font size="2" face="serif">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</font></p>
<table width="100%" cellspacing="0" cellpadding="0" border="0">
<tr valign="top">
<td width="3%"><img src="emptybox.gif" width="12" height="12"></td>
<td align="left"><font size="2" face="serif">Written communications pursuant
    to Rule 425 under the Securities Act (17 CFR 230.425)</font></td>
</tr>
</table>
<table width="100%" cellspacing="0" cellpadding="0" border="0">
<tr valign="top">
  <td>&nbsp;</td>
  <td align="left">&nbsp;</td>
</tr>
<tr valign="top">
<td width="3%"><img src="emptybox.gif" width="12" height="12"></td>
<td align="left"><font size="2" face="serif">Soliciting material pursuant to
    Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</font></td>
</tr>
</table>
<table width="100%" cellspacing="0" cellpadding="0" border="0">
<tr valign="top">
  <td>&nbsp;</td>
  <td align="left">&nbsp;</td>
</tr>
<tr valign="top">
<td width="3%"><img src="emptybox.gif" width="12" height="12"></td>
<td align="left"><font size="2" face="serif">Pre-commencement communications
    pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</font></td>
</tr>
</table>
<table width="100%" cellspacing="0" cellpadding="0" border="0">
<tr valign="top">
  <td>&nbsp;</td>
  <td align="left">&nbsp;</td>
</tr>
<tr valign="top">
<td width="3%"><img src="emptybox.gif" width="12" height="12"></td>
<td align="left"><font size="2" face="serif">Pre-commencement communications
    pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</font></td>
</tr>
</table>
<p align="center">&nbsp;</p>
<hr noshade align="center" width="100%" size="2">
<div style="page-break-before:always"></div>
<page>
<p align="left"><font size="2" face="serif"><b>Item 1.01.&nbsp;&nbsp;&nbsp;Entry into a Material
Definitive Agreement.</b></font></p>
<p align="left"><font size="2" face="serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)  (1)  <i><u>Director Stock
 Awards</u></i>.<i></i> Our directors were reelected to the Applera Corporation (the &#147;Company&#148;) Board
 of Directors (the &#147;Board&#148;) at our 2006 Annual Meeting of Stockholders, which was held on October 19,
 2006 (the &#147;2006 Annual Meeting&#148;).  In connection with their reelection, on October 19, 2006, the
Management Resources Committee of our Board (the &#147;MRC&#148;) granted to each director an award of 2,600
shares of Applera Corporation &#150; Applied Biosystems Group Common Stock (&#147;Applera-Applied Biosystems
stock&#148;) pursuant to the Applera Corporation/Applied Biosystems Group Amended and Restated 1999 Stock Incentive
 Plan (the
&#147;Applera-Applied Biosystems Plan&#148;) and 1,000 shares of Applera Corporation &#150; Celera Genomics
 Group Common Stock (&#147;Applera-Celera Genomics stock&#148;) pursuant to the Applera Corporation/Celera
Genomics Group Amended and Restated 1999 Stock Incentive Plan (the &#147;Applera-Celera Genomics Plan&#148;).
 Each of these awards will vest on the date immediately preceding the Applera 2007 Annual Meeting of
 Stockholders and will be forfeited by a director, subject to certain exceptions, if the director ceases
to serve as a member of the Board prior to that date.  Prior to vesting, a director has the right to
receive cash dividends and to vote but may not transfer or otherwise dispose of the shares.</font></p>
<p align="left"><font size="2" face="serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2)  <i><u>Director
        Stock Options</u></i><u>.</u><i></i>  In connection with the reelection
        of our directors at the 2006 Annual Meeting, on October 19, 2006, the
        MRC granted to each director stock options for 9,000 shares
        of Applera-Applied Biosystems stock pursuant to the Applera-Applied Biosystems
        Plan and 3,600 shares of Applera-Celera Genomics stock pursuant to the
        Applera-Celera Genomics Plan. The options become exercisable in four
        equal annual installments commencing on October 19, 2007, the first anniversary
        of the grant, and have a term of ten years. The exercise price for the
        Applera-Applied Biosystems stock options is $33.74 per share, which was
        the fair market value of a share of Applera-Applied Biosystems stock
        on October 19, 2006, as determined in accordance with the Applera-Applied
        Biosystems Plan. The exercise price for the Applera-Celera Genomics stock
        options is $14.50 per share, which was the fair market value of a share
        of Applera-Celera Genomics stock on October 19, 2006, as determined in
        accordance with the Applera-Celera Genomics Plan.</font></p>
<p align="left"><font size="2" face="serif"><b>Item 5.02.&nbsp;&nbsp;&nbsp;Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.</b></font></p>
<p align="left"><font size="2" face="serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b>(b)</b> On
    October 20, 2006, the Company announced that Catherine M. Burzik had resigned
    her position as Senior Vice President and President, Applied
    Biosystems Group, and that Tony L. White, Chairman, President, and Chief
    Executive Officer of the Company, had become interim president of the Applied
    Biosystems Group. These management changes were effective October 19, 2006.
    Attached hereto as Exhibit 99.1 and incorporated by reference into this
    Item is the text of the Company&#146;s October 20, 2006, press release announcing
    these changes.</font></p>
<p align="left"><font size="2" face="serif"><b>Item 9.01.&nbsp;&nbsp;&nbsp;Financial Statements and Exhibits.</b></font></p>
<p align="left"><font size="2" face="serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b><i>(d) Exhibits.</i></b></font></p>
<p align="left"><font size="2" face="serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following exhibits are filed with this Report:</font></p>
<table width="100%" cellspacing="0" cellpadding="0" border="0">
<tr valign="top">
  <td width="4%">&nbsp;</td>
<td width="10%"><font size="2" face="serif"><i>Exhibit No.</i></font></td>
<td width="2%"><font size="2" face="serif">&nbsp;</font></td>
<td align="left"><font size="2" face="serif"><i>Description</i></font></td>
</tr>
<tr valign="top">
  <td width="4%">&nbsp;</td>
  <td>&nbsp;</td>
  <td>&nbsp;</td>
  <td align="left">&nbsp;</td>
</tr>
<tr valign="top">
  <td width="4%">&nbsp;</td>

<td><font size="2" face="serif">99.1</font></td>
<td>&nbsp;</td>
<td align="left">
<font size="2" face="serif">Press Release issued October 20, 2006.</font></td>
</tr>
</table>
<p align="center">&nbsp;</p>
<hr noshade align="center" width="100%" size="2">
<div style="page-break-before:always"></div>
<page>
<p align="center"><font size="2" face="serif"><b>SIGNATURES</b></font></p>
<p align="left"><font size="2" face="serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</font></p>
<table width="100%" cellspacing="0" cellpadding="0" border="0">
<tr valign="top">
  <td>&nbsp;</td>
  <td colspan="2"><font size="2" face="serif"><b>APPLERA CORPORATION</b></font></td>
  </tr>
<tr valign="top">
  <td>&nbsp;</td>
  <td>&nbsp;</td>
  <td align="left">&nbsp;</td>
</tr>
<tr valign="top">
<td width="50%"><font size="2" face="serif">&nbsp;</font></td>
<td width="3%"><font size="2" face="serif">By: </font></td>
<td align="left"><font size="2" face="serif"> <u>/s/ Thomas P. Livingston</u></font></td>
</tr>
<tr valign="top">
<td><font size="2" face="serif">&nbsp;</font></td>
<td><font size="2" face="serif">&nbsp;</font></td>
<td align="left"><font size="2" face="serif">Thomas P. Livingston</font></td>
</tr>
<tr valign="top">
<td><font size="2" face="serif">&nbsp;</font></td>
<td><font size="2" face="serif">&nbsp;</font></td>
<td align="left"><font size="2" face="serif">Vice President and Secretary</font></td>
</tr>
</table>
<p align="left"><font size="2" face="serif">Dated: October 20, 2006</font></p>
<p align="center">&nbsp;</p>
<hr noshade align="center" width="100%" size="2">
<div style="page-break-before:always"></div>
<page>
<p align="center"><font size="2" face="serif"><b>EXHIBIT INDEX</b></font></p>
<table width="100%" cellspacing="0" cellpadding="0" border="0">
<tr valign="top">
<td width="10%"><font size="2" face="serif"><i>Exhibit No.</i></font></td>
<td width="2%"><font size="2" face="serif">&nbsp;</font></td>
<td align="left"><font size="2" face="serif"><i>Description</i></font></td>
</tr>
<tr valign="top">
  <td>&nbsp;</td>
  <td>&nbsp;</td>
  <td align="left">&nbsp;</td>
</tr>
<tr valign="top">
<td><font size="2" face="serif">99.1</font></td>
<td>&nbsp;</td>
<td align="left">
<font size="2" face="serif">Press Release issued October 20, 2006.</font></td>
</tr>
</table>
<p align="center">&nbsp;</p>
<hr noshade align="center" width="100%" size="2">
</body>
</html>
[{"type": "8-K", "sequence": "1", "filename": "b415357_8k.htm", "description": "FORM 8K", "secsgml_size_bytes": 11442}]
{"company-data": {"conformed-name": "APPLERA CORP", "cik": "0000077551", "assigned-sic": "3826", "irs-number": "061534213", "state-of-incorporation": "DE", "fiscal-year-end": "0630"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "001-04389", "film-number": "061156136"}, "business-address": {"street1": "301 MERRITT 7", "city": "NORWALK", "state": "CT", "zip": "06851", "phone": "2038402000"}, "mail-address": {"street1": "301 MERRITT 7", "city": "NORWALK", "state": "CT", "zip": "06851"}, "former-company": [{"former-conformed-name": "PE CORP", "date-changed": "19990129"}, {"former-conformed-name": "PERKIN ELMER CORP", "date-changed": "19930601"}]}
Prepared and filed by St Ives Financial
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D. C.  20549
___________
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
October 19, 2006
Date of report (Date of earliest event reported)
APPLERA CORPORATION
(Exact name of registrant as specified in its charter)
Delaware
001-04389
06-1534213
(State or other jurisdiction
of incorporation)
(Commission
file
number)
(IRS Employer
Identification No.)
301 Merritt 7
Norwalk, Connecticut  06851
(Address of principal executive offices, including zip code)
(203) 840-2000
(Registrant's
telephone number, including area code)
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant
    to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to
    Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications
    pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications
    pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 1.01.   Entry into a Material
Definitive Agreement.
(a)  (1)
Director Stock
 Awards
.
Our directors were reelected to the Applera Corporation (the "Company") Board
 of Directors (the "Board") at our 2006 Annual Meeting of Stockholders, which was held on October 19,
 2006 (the "2006 Annual Meeting").  In connection with their reelection, on October 19, 2006, the
Management Resources Committee of our Board (the "MRC") granted to each director an award of 2,600
shares of Applera Corporation – Applied Biosystems Group Common Stock ("Applera-Applied Biosystems
stock") pursuant to the Applera Corporation/Applied Biosystems Group Amended and Restated 1999 Stock Incentive
 Plan (the
"Applera-Applied Biosystems Plan") and 1,000 shares of Applera Corporation – Celera Genomics
 Group Common Stock ("Applera-Celera Genomics stock") pursuant to the Applera Corporation/Celera
Genomics Group Amended and Restated 1999 Stock Incentive Plan (the "Applera-Celera Genomics Plan").
 Each of these awards will vest on the date immediately preceding the Applera 2007 Annual Meeting of
 Stockholders and will be forfeited by a director, subject to certain exceptions, if the director ceases
to serve as a member of the Board prior to that date.  Prior to vesting, a director has the right to
receive cash dividends and to vote but may not transfer or otherwise dispose of the shares.
(2)
Director
        Stock Options
.
In connection with the reelection
        of our directors at the 2006 Annual Meeting, on October 19, 2006, the
        MRC granted to each director stock options for 9,000 shares
        of Applera-Applied Biosystems stock pursuant to the Applera-Applied Biosystems
        Plan and 3,600 shares of Applera-Celera Genomics stock pursuant to the
        Applera-Celera Genomics Plan. The options become exercisable in four
        equal annual installments commencing on October 19, 2007, the first anniversary
        of the grant, and have a term of ten years. The exercise price for the
        Applera-Applied Biosystems stock options is $33.74 per share, which was
        the fair market value of a share of Applera-Applied Biosystems stock
        on October 19, 2006, as determined in accordance with the Applera-Applied
        Biosystems Plan. The exercise price for the Applera-Celera Genomics stock
        options is $14.50 per share, which was the fair market value of a share
        of Applera-Celera Genomics stock on October 19, 2006, as determined in
        accordance with the Applera-Celera Genomics Plan.
Item 5.02.   Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.
(b)
On
    October 20, 2006, the Company announced that Catherine M. Burzik had resigned
    her position as Senior Vice President and President, Applied
    Biosystems Group, and that Tony L. White, Chairman, President, and Chief
    Executive Officer of the Company, had become interim president of the Applied
    Biosystems Group. These management changes were effective October 19, 2006.
    Attached hereto as Exhibit 99.1 and incorporated by reference into this
    Item is the text of the Company's October 20, 2006, press release announcing
    these changes.
Item 9.01.   Financial Statements and Exhibits.
(d) Exhibits.
The following exhibits are filed with this Report:
Exhibit No.
Description
99.1
Press Release issued October 20, 2006.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
APPLERA CORPORATION
By:
/s/ Thomas P. Livingston
Thomas P. Livingston
Vice President and Secretary
Dated: October 20, 2006
EXHIBIT INDEX
Exhibit No.
Description
99.1
Press Release issued October 20, 2006.